Saturday, February 21, 2026
18.4 C
Bengaluru

Indian Pharma Market (IPM) Highlights – January 2025


Overall IPM Performance:

  • Monthly Growth: IPM monthly growth reached 8.4% in January 2025, following a pattern of significant monthly fluctuations throughout the year.
  • MAT Growth: The Moving Annual Total (MAT) growth for January 2025 slightly increased to 7.7%, up from 7.6% in December 2024.

Acute vs. Chronic Segment Analysis:

  • Chronic Segment Dominance: The chronic segment continued to outperform the acute segment, with a MAT growth of 9.9% compared to 6.3% for the acute segment in January 2025.
  • Growth Rate Declines: While the chronic segment’s growth rate only slightly decreased (by 1.1%), the acute segment experienced a more substantial decline (3.2%) compared to January 2024.

Monthly Growth Trends:

  • Overall Sales Increase: Overall monthly sales increased by 1.1% in January 2025 compared to December 2024. Acute segment sales rose by a more modest 0.4% during the same period.
  • Chronic Segment Outperformance: The chronic segment demonstrated faster growth (9.3%) than the acute segment (7.8%) in January 2025 relative to January 2024 sales.

Top Performing Companies:

  • The report lists the top companies in IPM for January 2025, ranked by market share and growth. Sun Pharmaceuticals held the top spot.

Top Performing Brands:

  • The report details top-performing brands, categorized by manufacturer and market share, showing Foracort as the leading brand in January 2025.

Therapeutic Class and Indian vs. MNC Trend:

  • Cardiac therapies led in market share, followed by anti-infectives and gastrointestinal treatments.
  • MNCs slightly surpassed the growth of Indian companies in both the acute and overall segments.

Top New Introductions (NI) in IPM (Last 12 Months):

  • A total of 3219 new brands were launched in the last year, contributing 0.5% to IPM sales and 6.5% to IPM growth for MAT January 2025. Gastrointestinal brands represented the largest value among these new introductions.

Top 30 Metros Performance:

  • The top 30 cities displayed slightly higher growth (8.8%) than overall IPM growth (7.7%). Delhi maintained the fastest growth rate (13.5%) among the six major metropolitan areas.

Regional Performance:

  • The North zone held the largest market share (41%), while the South zone demonstrated the highest growth (8.5%). Delhi showed the highest growth among states (13.5%), followed by Chhattisgarh and Haryana.

Fastest-Growing Companies (Top 50):

  • The report identified the fastest-growing companies (Top 50) by region, showcasing varying growth rates across different zones. Samarth led the West zone.

Fastest-Growing Companies (Top 51-100):

  • This section lists the top 51-100 fastest-growing companies by region, offering further performance breakdown across geographical areas.

East Zone Top Companies and Brands:

  • The report includes detailed information on the top companies and brands within the East Zone, showing performance metrics such as market share and growth rate.

West Zone Top Companies and Brands:

  • Similar detailed information as the East Zone is provided for the West Zone, with company rankings and brand performance data.

South Zone Top Companies and Brands:

  • The report offers the same comprehensive data on top companies and brands for the South Zone, providing insights into regional market dynamics.

A MedicinManAI Feature

Hot this week

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Topics

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...
spot_img

Related Articles

spot_imgspot_img